August 3, 2021 -- Catalent, a provider of delivery technologies and development and manufacturing solutions for drugs, biologics, and cell and gene therapies, announced that 97% of its electricity usage is procured from renewable energy sources such as wind, solar, hydroelectric, and biomass.
The announcement aligns with a letter of commitment that Catalent recently signed with the Science-Based Targets initiative (SBTi). SBTi sets actionable, science-based greenhouse gas emission reduction targets to limit global warming. The commitment includes calculating and reducing direct and indirect emissions as the over 1,600 participating companies in SBTi evolve and grow.
The company will purchase renewable energy certificates for all of its operating sites in North America, South America, and Europe, as well as most of its Asia-based facilities.
"As a leader in the growing CDMO [contract development and manufacturing organization] industry, we need to demonstrate our shared commitment, sense of urgency, and value in contributing to the responsibility and long-term sustainability of the entire biopharma sector," said John Chiminski, chair and chief executive officer of Catalent, in a statement.
Already have an account? Sign in Here
To access all ScienceBoard content create a free account now: